Neuroprevention: A new challenge?

Revue Neurologique

Volumn 168, Issue 11, 2012, Pages 796-801

  Corvol, J C ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Alzheimer's disease; Neurodegenerative disorders; Parkinson's disease; Prevention

Indexed keywords

CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DISEASE MARKER; HEALTH ECONOMICS; HIGH RISK POPULATION; MEDICAL ETHICS; PARKINSON DISEASE; SYMPTOM;

EID: 84869088132     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2012.07.001     Document Type: Review

References (49)

1. W.F. Abdo, B.R. Bloem, W.J. Van Geel, R.A. Esselink, and M.M. Verbeek CSF neurofilament light-chain and tau differentiate multiple system atrophy from Parkinson's disease Neurobiol Aging 28 2007 742 747
2. H.W. Berendse, and M.M. Ponsen Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging Parkinsonism Relat Disord 15 Suppl. 3 2009 S26 S30
3. D. Berg, C. Siefker, P. Ruprecht-Dorfler, and G. Becker Relationship of substantia nigra echogenicity and motor function in elderly subjects Neurology 56 2001 13 17
4. D. Berg Tracking of striatal degeneration in prediagnostic Parkinson's disease: first steps into a promising future Lancet Neurol 10 2011 775 776
5. B. Borroni, M. Malinverno, F. Gardoni, A. Alberici, L. Parnetti, and E. Premi Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy Neurology 71 2008 1796 1803
6. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
7. J. Brettschneider, A. Petzold, S.D. Sussmuth, G.B. Landwehrmeyer, A.C. Ludolph, and J. Kassubek Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes Mov Disord 21 2006 2224 2227
8. J. Brettschneider, A. Petzold, S.D. Sussmuth, A.C. Ludolph, and H. Tumani Axonal damage markers in cerebrospinal fluid are increased in ALS Neurology 66 2006 852 856
9. R. Constantinescu, H. Zetterberg, B. Holmberg, and L. Rosengren Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders Parkinsonism Relat Disord 15 2009 205 212
10. E.H. Corder, A.M. Saunders, N.J. Risch, W.J. Strittmatter, D.E. Schmechel, and P.C. Gaskell Jr. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Nat Genet 7 1994 180 184
11. L.M. de Lau, and M.M. Breteler Epidemiology of Parkinson's disease Lancet Neurol 5 2006 525 535
12. M. Dejesus-Hernandez, I.R. Mackenzie, B.F. Boeve, A.L. Boxer, M. Baker, and N.J. Rutherford Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS Neuron 72 2011 245 256
13. O.M. El-Agnaf, S.A. Salem, K.E. Paleologou, L.J. Cooper, N.J. Fullwood, and M.J. Gibson Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma FASEB J 17 2003 1945 1947
14. M. Eller, and D.R. Williams alpha-Synuclein in Parkinson disease and other neurodegenerative disorders Clin Chem Lab Med 49 2011 403 408
15. A. Gaenslen, B. Unmuth, J. Godau, I. Liepelt, A. Di Santo, and K.J. Schweitzer The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study Lancet Neurol 7 2008 417 424
16. J.F. Gagnon, R.B. Postuma, S. Mazza, J. Doyon, and J. Montplaisir Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases Lancet Neurol 5 2006 424 432
17. C. Goizet, G. Lesca, and A. Durr Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias Neurology 59 2002 1330 1336
18. C. Hawkes Olfaction in neurodegenerative disorder Mov Disord 18 2003 364 372
19. B. Holmberg, L. Rosengren, J.E. Karlsson, and B. Johnels Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease Mov Disord 13 1998 70 77
20. B. Holmberg, B. Johnels, P. Ingvarsson, B. Eriksson, and L. Rosengren CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes Parkinsonism Relat Disord 8 2001 23 31
21. B. Holmberg, B. Johnels, K. Blennow, and L. Rosengren Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy Mov Disord 18 2003 186 190
22. A. Iranzo, J.L. Molinuevo, J. Santamaria, M. Serradell, M.J. Marti, and F. Valldeoriola Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study Lancet Neurol 5 2006 572 577
23. N. Itoh, H. Arai, K. Urakami, K. Ishiguro, H. Ohno, and H. Hampel Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease Ann Neurol 50 2001 150 156
24. C.R. Jack Jr., V.J. Lowe, M.L. Senjem, S.D. Weigand, B.J. Kemp, and M.M. Shiung 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 131 2008 665 680
25. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
26. K. Kantarci, S.D. Weigand, S.A. Przybelski, M.M. Shiung, J.L. Whitwell, and S. Negash Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS Neurology 72 2009 1519 1525
27. C. LePen, S. Wait, F. Moutard-Martin, M. Dujardin, and M. Ziegler Cost of illness and disease severity in a cohort of French patients with Parkinson's disease Pharmacoeconomics 16 1999 59 69
28. S. Lesage, A. Durr, M. Tazir, E. Lohmann, A.L. Leutenegger, and S. Janin LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs N Engl J Med 354 2006 422 423
29. B. Mollenhauer, M. Bibl, H. Esselmann, P. Steinacker, C. Trenkwalder, and J. Wiltfang Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm 114 2007 919 927
30. B. Mollenhauer, J.J. Locascio, W. Schulz-Schaeffer, F. Sixel-Doring, C. Trenkwalder, and M.G. Schlossmacher alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Lancet Neurol 10 2011 230 240
31. L. Mosconi, S. Sorbi, M.J. de Leon, Y. Li, B. Nacmias, and P.S. Myoung Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease J Nucl Med 47 2006 1778 1786
32. M.A. Nalls, V. Plagnol, D.G. Hernandez, M. Sharma, U.M. Sheerin, and M. Saad Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies Lancet 377 2011 641 649
33. R. Nandhagopal, L. Kuramoto, M. Schulzer, E. Mak, J. Cragg, and C.S. Lee Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study Brain 132 2009 2970 2979
34. M. Noguchi, M. Yoshita, Y. Matsumoto, K. Ono, K. Iwasa, and M. Yamada Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration J Neurol Sci 237 2005 61 65
35. C.W. Olanow, O. Rascol, R. Hauser, P.D. Feigin, J. Jankovic, and A. Lang A double-blind, delayed-start trial of rasagiline in Parkinson's disease N Engl J Med 361 2009 1268 1278
36. M.B. Patwardhan, D.C. McCrory, D.B. Matchar, G.P. Samsa, and O.T. Rutschmann Alzheimer disease: operating characteristics of PET - a meta-analysis Radiology 231 2004 73 80
37. P. Peran, A. Cherubini, F. Assogna, F. Piras, C. Quattrocchi, and A. Peppe Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature Brain 133 2010 3423 3433
38. M.M. Ponsen, D. Stoffers, J. Booij, B.L. van Eck-Smit, E. Wolters, and H.W. Berendse Idiopathic hyposmia as a preclinical sign of Parkinson's disease Ann Neurol 56 2004 173 181
39. R.B. Postuma, J.F. Gagnon, M. Vendette, M.L. Fantini, J. Massicotte-Marquez, and J. Montplaisir Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder Neurology 72 2009 1296 1300
40. R.B. Postuma, and J. Montplaisir Predicting Parkinson's disease - why, when, and how? Parkinsonism Relat Disord 15 Suppl 3 2009 S105 S109
41. A.E. Renton, E. Majounie, A. Waite, J. Simon-Sanchez, S. Rollinson, and J.R. Gibbs A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD Neuron 72 2011 257 268
42. J.O. Rinne, D.J. Brooks, M.N. Rossor, N.C. Fox, R. Bullock, and W.E. Klunk 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 2010 363 372
43. G.W. Ross, H. Petrovitch, R.D. Abbott, C.M. Tanner, J. Popper, and K. Masaki Association of olfactory dysfunction with risk for future Parkinson's disease Ann Neurol 63 2008 167 173
44. M. Sarazin, and B. Dubois Mild Cognitive Impairment or pre-demential Alzheimer's disease? Rev Neurol (Paris) 158 2002 S30 S34
45. C.H. Schenck, S.R. Bundlie, and M.W. Mahowald Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder Neurology 46 1996 388 393
46. M. Shi, and J. Zhang CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease Lancet Neurol 10 2011 681 [Author's reply: 681-3]
47. S.J. Tabrizi, D.R. Langbehn, B.R. Leavitt, R.A. Roos, A. Durr, and D. Craufurd Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Lancet Neurol 8 2009 791 801
48. D. Tabuteau Office de prospective de santé Rapport 2008 2008 202
49. A. Tibben Predictive testing for Huntington's disease Brain Res Bull 72 2007 165 171